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Prognostic Impact of Platelet-Derived Growth Factors in
Non-small Cell Lung Cancer Tumor and Stromal Cells
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Lill-Tove Busund, MD, PhD,‡§ and Roy M. Bremnes, MD, PhD*†
Background: In tumor angiogenesis there is a complex interplay
between endothelial, stromal, and tumor cells (neoplastic epithe-
lial cells). Platelet-derived growth factors (PDGFs) and receptors
(PDGFRs) are pivotal in this interaction, and important targets in
novel antiangiogenic therapies. This study investigates the prognos-
tic impact of these molecular markers in tumor cells and tumor
stroma of resected non-small cell lung cancer (NSCLC) tumors.
Methods: Tumor tissue samples from 335 resected patients with
stage I to IIIA NSCLC were obtained and tissue microarrays were
constructed from duplicate cores of tumor cells and tumor-related
stroma from each specimen. Immunohistochemistry was used to
evaluate the expression of the molecular markers PDGF-A, -B, -C,
and -D and PDGFR- and -.
Results: In univariate analyses, high tumor cell expression of
PDGF-B (p  0.001), PDGF-C (p  0.01), and PDGFR- (p 
0.026) were negative prognostic indicators for disease-specific sur-
vival. In tumor stroma, high expression of PDGF-A (p  0.009),
PDGF-B (p  0.04), PDGF-D (p  0.019), and PDGFR- (p 
0.019) correlated with good prognosis. In multivariate analyses, high
tumor cell PDGF-B (p  0.001) and PDGFR- (p  0.047)
expression were independent negative prognostic factors for dis-
ease-specific survival, whereas in stromal cells high PDGF-A (p 
0.001) expression had an independent positive survival impact.
Conclusion: Our results indicate PDGF-B and PDGFR- inhibition
as an interesting approach in NSCLC treatment, but also demon-
strates the importance of understanding the cellular crosstalk be-
tween endothelial, stromal, and tumor cells when targeting PDGF
markers.
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Lung cancer is the leading cause of cancer-related mortalityin both men and women.1 Although chemotherapy re-
cently has shown promising results in the adjuvant clinical
setting and there has been some progress in the treatment of
locally advanced and advanced disease, treatment outcomes
for non-small cell lung cancer (NSCLC) patients are in
general disappointing.2–5 Thus, clinical research on new treat-
ment strategies is warranted. In the pipeline for new NSCLC
therapies, several agents involve directly or indirectly plate-
let-derived growth factors (PDGFs) and its receptors (PDG-
FRs), e.g., sorafenib, sunitunib, imatinib, and bevacizumab.6,7
The PDGF family consists of five isoforms of A-, B-,
C-, and -D polypeptide chains that is homodimers PDGF-AA,
-BB, -CC, -DD, and a hetereodimer PDGF-AB.8,9 The PDGF
isoforms exert their cellular effects by binding to structurally
similar - and -tyrosine kinase PDGF receptors. PDGF-AA,
-AB, -BB, and CC dimers bind to the -receptor with high
affinity, whereas PDGF-BB and -DD dimers bind preferen-
tially to the -receptor.10,11
PDGF ligands and receptors are of major importance in
angiogenesis.10–12 PDGF-B and PDGFR- is required for
recruitment of pericytes, which are periendothelial smooth
muscle-like cells, which modulate endothelial cell function, and
in maturation of the microvasculature.13 Recent studies have
emphasized the significance of tumor-derived PDGF-A (and
potentially PDGF-C) and PDGFR- signaling in recruitment of
the angiogenic stroma to produce vascular endothelial growth
factor-A (VEGF-A), and other angiogenic factors.14
To our knowledge, only two previous studies have
explored the prognostic relevance of PDGFs/PDGFRs ex-
pression and survival in NSCLC patients.15,16 Kawai et al.15
found tumor cell PDGF-B expression, by immunohistochem-
istry (IHC), to predict a negative outcome in 92 resected
specimens whereas Shikada et al.16 observed that PDGF-A
had a negative prognostic impact in univariate analysis. In the
latter study, they also found PDGF-A to be an autocrine
(signaling affects cells of the same type as secreted), and
probably paracrine stimulator (signaling in which the target
cell is a different cell type close to the signal releasing cell),
yielding an essential contribution to the expression of vascu-
lar endothelial growth factor (VEGF).
As new agents, involving PDGF/PDGFR inhibition, are
being clinically evaluated for NSCLC treatment, further knowl-
edge about these ligands and receptors and the complex
interplay between endothelial, stromal, and tumor cells is
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warranted. We have previously reported on the importance of
VEGFs and their receptors in both tumor cells and stroma.17
This is the first report on the prognostic significance of
PDGF-A, -B, -C, and -D and PDGFR- and - expression in
both tumor cells and in stroma of resected NSCLC patients.
PATIENTS AND METHODS
Patients and Clinical Samples
Primary tumor tissues from anonymized patients diag-
nosed with NSCLC pathologic stage I to IIIA at the Univer-
sity Hospital of Northern Norway and Nordland Central
Hospital from 1990 through 2004 were used in this retrospec-
tive study. In total, 371 patients were registered from the
hospital database. Of these, 36 patients were excluded from
the study because of: (i) Radiotherapy (RT) or chemotherapy
before surgery (n 10); (ii) Other malignancy within 5 years
before NSCLC diagnosis (n  13); (iii) Inadequate paraffin-
embedded fixed tissue blocks (n  13). Adjuvant chemother-
apy was not introduced in Norway during this period (1990–
2004). Thus, 335 patients with complete medical records and
adequate paraffin-embedded tissue blocks were eligible.
This report includes follow-up data as of September 30,
2005. The median follow-up was 96 (range, 10–179) months.
Complete demographic and clinical data were collected ret-
rospectively. Formalin-fixed and paraffin-embedded tumor
specimens were obtained from the archives of the Depart-
ments of Pathology at University Hospital of Northern Nor-
way and Nordland Central Hospital. The tumors were staged
according to the International Union Against Cancer’s tumor,
node, metastasis classification and histologically subtyped
and graded according to the World Health Organization
guidelines.18 The National Data Inspection Board and The
Regional Committee for Research Ethics approved the study.
Microarray Construction
All lung cancer cases were histologically reviewed by
two pathologists (S.A.-S. and K. A.-S.) and the most repre-
sentative areas of tumor cells (neoplastic epithelial cells) and
tumor stroma were carefully selected and marked on the
hematoxylin and eosin slide, and sampled for the tissue
microarray blocks (TMAs). The TMAs were assembled using
a tissue-arraying instrument (Beecher Instruments, Silver
Springs, MD). The detailed methodology has been previously
reported.17 Briefly, we used a 0.6 mm diameter stylet, and the
study specimens were routinely sampled with two replicate
core samples (different areas) of neoplastic tissue and two of
tumor stroma. Both normal lung tissue localized distant from
the primary tumor, and one slide with normal lung tissue
samples from 20 patients without a cancer diagnosis, were
used as negative controls.
To include all core samples, eight tissue array blocks
were constructed. Multiple 5-m sections were cut with a
Micron microtome (HM355S) and stained by specific anti-
bodies for IHC analysis.
Immunohistochemistry
The applied antibodies were subjected to in-house val-
idation by the manufacturer for IHC analysis on paraffin-
embedded material. The antibodies used in the study were as
follows: PDGF-AA (goat polyclonal; AB-221-NA; R and D
Systems; 1:200), PDGF-AB/BB (rabbit polyclonal; RB-9257;
Neomarkers; 1:15), PDGF-CC (goat polyclonal; GT15151;
Neuromics; 1:80), PDGF-DD (goat polyclonal; AF1159; R
and D Systems; 1:400), PDGFR- (rabbit polyclonal; RB-
9027; Neomarkers; 1:75), and PDGFR- (rabbit polyclonal;
RB-9032; Neomarkers; 1:25).
Sections were deparaffinised with xylene and rehy-
drated with ethanol. Regarding ligands (PDGF-A, -B, -C, and
-D), antigen retrieval was performed by placing the specimen
in 0.01 M citrate buffer at pH 6.0 and exposed to repeated (
2) microwave heating of 10 minutes at 450W. PDGF-A, -B,
and -C were stained using peroxydase/diamino benzidine
(Dako EnVision  System-Horseadish peroxidase/diamino
benzidine). The primary antibodies were incubated for 30
minutes in room temperature. PDGF-D was visualized by
adding a secondary antibody conjugated with Biotin, fol-
lowed by an avidin/biotin/peroxydase complex (Vectastein
avidin-biotin-peroxidase complex Elite kit from Vector Lab-
oratories). The primary antibody was incubated over night at
4°C. Finally, all slides were counterstained with hematoxylin
to visualize the nuclei.
The receptors (PDGFR- and -) were stained using
Ventana BenchMark XT (Ventana Medical Systems Inc.),
procedure iView Diamino benzidine. Antigen retrieval was
done in Tris/ethylenediaminetetraacetic acid buffer at pH 8.4
for 30 minutes (PDGFR-) or 60 minutes (PDGFR-) at
37°C. The primary antibodies were incubated for 30 minutes
in room temperature.
For each antibody, included negative staining controls,
all TMA stainings were done in a single experiment.
Scoring of Immunohistochemistry
By light microscopy, representative and viable tissue
sections were scored semiquantitatively for cytoplasmic
staining. The dominant staining intensity in both tumor cells
and stromal cells was scored as: 0 negative; 1 weak; 2
intermediate; 3  strong (Figure 1). The cell density of the
stroma was scored as: 1  low density; 2  intermediate
density; 3  high density (Figure 1). All samples were
anonymized and independently scored by two pathologists
(S.A.-S. and K.A.-S.). In case of disagreement, the slides
were reexamined and a consensus was reached by the ob-
servers. In most tumor cores and in some stromal cores there
is a mixture of stromal cells and tumor cells. Nevertheless, by
morphologic criteria we have only scored staining intensity of
tumor cells in tumor cores and intensity and density of
stromal cells in stromal cores. When assessing a variable for
a given core, the observers were blinded to the scores of the
other variables and to outcome. The interobserver scoring
agreement has been previously found valid in the same
TMA-blocks for one ligand and one receptor with similar
cytoplasmic staining.17 After categorizing into high and low
expression group, the percentage discordance among the
pathologists was tumor cell ligand 8%, stromal ligand 8%,
tumor cell receptor 2%, and stromal receptor 4%. Mean score
for duplicate cores from each individual was calculated sep-
arately in tumor cells and stroma. High expression in tumor
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cells was defined as score 1.5 (PDGF-C), 2 (PDGF-A,
PDGFR-, and PDGFR-), or  3 (PDGF-B and PDGF-D).
Stromal expression was calculated by summarizing density
score (1–3) and intensity score (0–3) before categorizing into
low and high expression. High expression in stroma was
defined as score 2.5 (PDGFR-), 4 (PDGF-B), 4.5
(PDGF-A, PDGF-C, and PDGFR-), or 5.5 (PDGF-D).
Statistical Methods
All statistical analyses were done using the statistical
package SPSS (Chicago, IL), version 14. The 2 test and
Fisher exact test were used to examine the association be-
tween molecular marker expression and various clinicopath-
ological parameters. Univariate analysis was done by using
the Kaplan-Meier method. Statistical significance between
survival curves was assessed by the log-rank test. Disease-
specific survival (DSS) was determined from the date of
surgery to the time of lung cancer death. To assess the
independent value of different pretreatment variables on sur-
vival, in the presence of other variables, multivariate analysis
was carried out using the Cox proportional hazards model.
Only variables of significant value from the univariate anal-
ysis were entered into the Cox regression analysis. Probabil-
ity for stepwise entry and removal was set at 0.05 and 0.10,
respectively.
RESULTS
Clinocopathologic Variables
Demographic, clinical, and histopathologic variables
are shown in Table 1. The median age was 67 (range, 28–85)
years and the majority of patients were male (76%). The
NSCLC tumors comprised 191 squamous cell carcinomas
(SCCs), 95 adenocarcinomas, 31 large-cell carcinomas
(LCCs), and 18 bronchioalveolar carcinomas (BACs). Be-
cause of nodal metastasis or nonradical surgical margins, 59
(18%) patients received postoperative RT.
Expression of Platelet-Derived Growth Factors/
Platelet-Derived Growth Factor Receptors and
Their Correlations
PDGFs/PDGFRs were expressed in the cytoplasm of
tumor cells. On the basis of only morphologic criteria without
any double IHC, we estimated more than 50% of normal
pneumocytes in control cores to be stained by all antibodies,
except PDGFR- where less than 50% were stained. In tumor
stroma and in control cores, more than 50% of inflammatory
cells (macrophages, lymphocytes, granulocytes, and plasma
cells) were stained, except for PDGFR- where less than
50% were stained. Nearly all fibroblast-like cells were
stained, only PDGFR-  stained less than 50% of these cells.
In control cores, most vascular endothelium was stained for
PDGF-A, -B, and -D and PDGFR-, less than 50% for
PDGF-C and none for PDGFR-. The majority of vascular
smooth muscle cells were stained, except for PDGFR- and
PDGFR- where less than 50% were stained.
No correlation was observed between tumor or stromal
cell PDGFs/PDGFRs expression versus age, performance
status, weight loss, tumor differentiation, or vascular infiltra-
tion. Among the ligands, tumor cell PDGF-A was less fre-
quently expressed in LCC (high expression; LCC 23%, BAC
FIGURE 1. Immunohistochemical analysis of
TMA of NSCLC representing different score for
tumor cell PDGFR- and PDGF-A; A, Stromal
PDGF-A high score (density 3, intensity 3); B,
Stromal PDGF-A low score (density 1, intensity
0); C, Tumor cell PDGFR- score 3; D, Tumor cell
PDGFR- score 1. TMA, tissue microarray block;
NSCLC, non-small cell lung cancer; PDGF, plate-
let-derived growth factor.
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45%, SCC 56%, adenocarcinomas 56%, p  0.002) and less
often in pathologic stage I (high expression; p-stage I 45%,
p-stage II 63%, p-stage III 67%, p 0.004) Stromal PDGF-C
was more often expressed in women (high expression; women
44%, men 30%, p  0.029) whereas stromal PDGF-D expres-
sion was observed more frequently in LCC (high expression;
LCC 23%, BAC 5%, SCC 6%, adenocarcinomas 13%, p 
0.002) and in p-stage I (high expression; p-stage I 13%, p-stage
II 4%, p-stage III 3%, p 0.032). Among receptors, tumor cell
PDGFR- expression was more often seen in women (high
expression; women 71%, men 57%, p 0.024) and less often
in SCC (high expression; LCC 77%, BAC 68%, SCC 51%,
adenocarcinomas 73%, p  0.001). Stromal PDGFR- was
more often expressed in SCC (high expression; LCC 38%,
BAC 35%, SCC 48%, adenocarcinomas 28%, p 0.046) and
stromal PDGFR- more often in women (high expression;
women 33%, men 17%, p  0.003).
Univariate Analysis
As shown in Table 1, the clinical variables performance
status (p  0.04), differentiation (p  0.001), surgical pro-
cedure (p  0.0009), stage (p  0.0001), histologic T-stage
(p  0.002), N-stage (p  0.0001), vascular infiltration (p 
0.0005), and postoperative RT (p  0.002) were all prognos-
tic indicators for DSS. The influence on survival by tumor
cell and stromal PDGF ligands and receptors are given in
Table 2 and in Figure 2. In univariate analysis, tumor cell
expression of PDGF-B (p 0.001; Figure 2B), PDGF-C (p
0.01) and PDGFR- (p  0.026; Figure 2C) and stromal
expression of PDGF-A (p  0.009; Figure 2A), PDGF-B
(p  0.04), PDGF-D (p  0.019), and PDGFR- (p  0.01)
were prognostic indicators for DSS.
Multivariate Cox Proportional Hazards Analysis
Results of the multivariate analysis are presented in
Table 3. Including all significant clinicopathological and
angiogenic variables from the univariate analysis, tumor cell
PDGF-B (p  0.001) and PDGFR- (p  0.047) expression,
stromal cell PDGF-A expression (p  0.001), performance
status (p  0.013), histologic T-stage (p  0.002), N-stage
(p  0.001) and vascular infiltration (p  0.003) appeared as
independent prognostic factors. High tumor cell PDGF-C
expression tended towards an independent negative impact on
survival, but did not reach statistical significance (p  0.13,
OR 1.90, confidence interval 95% 0.82–4.38).
Correlations Between Platelet-Derived Growth
Factors/Platelet-Derived Growth Factor
Receptors and Vascular Endothelial Growth
Factors/Vascular Endothelial Growth Factor
Receptors
We have previously reported results from this cohort on
VEGFs and vascular endothelial growth factor receptors
(VEGFRs).17 There are significant correlations between
PDGF-A and VEGF-A expression in tumor cell (r  0.29,
p  0.001; Table 4), between PDGF-A and VEGF-A in
stroma (r 0.30, p 0.001; Table 5), but not between tumor
cell PDGF-A and stromal VEGF-A (r  0.005, p  0.92).
There was also a significant correlation between VEGF-A
TABLE 1. Prognostic Clinicopathologic Variables as
Predictors for Disease-Specific Survival in 335 NSCLC
Patients (Univariate Analysis; Log-Rank Test)
Characteristic
Patients
(n)
Patients
(%)
Median
Survival
(mo)
5-Year
Survival
(%) p
Age
65 yr 156 47 104 57 0.62
65 yr 179 53 NR 58
Sex
Female 82 25 127 65 0.19
Male 253 75 84 55
Smoking
Never 15 5 19 43 0.13
Current 215 64 NR 60
Former 105 31 84 54
Performance status
ECOG 0 197 59 NR 62 0.04
ECOG 1 120 36 61 52
ECOG 2 18 5 36 40
Weight loss
10% 303 90 127 57 0.92
10% 32 10 NR 57
Histology
SCC 191 57 NR 65 0.30
Adenocarcinoma 95 28 52 44
BAC 18 5 NR 67
LCC 31 9 84 54
Differentiation
Poor 138 41 48 48 0.001
Moderate 144 43 NR 64
Well 53 16 NR 65
Surgical procedure
Lobectomy 
Wedgea
243 73 NR 61 0.0009
Pneumonectomy 92 27 35 46
Stage
I 212 63 NR 68 0.0001
II 91 27 41 46
IIIa 32 10 18 22
Tumor status
1 90 27 NR 75 0.002
2 218 65 84 52
3 27 8 42 43
Nodal status
0 232 69 NR 66 0.0001
1 76 23 37 43
2 27 8 18 20
Surgical margins
Free 307 92 127 58 0.34
Not free 28 8 64 51
Vascular infiltration
No 284 85 NR 61 0.0005
Yes 51 15 25 35
Postoperative
radiotherapy
No 276 82 NR 61 0.002
Yes 59 18 41 42
a Wedge, n  10.
NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group;
SCC, squamous cell carcinoma; BAC, bronchioalveolar carcinoma; LCC, large-cell
carcinoma; NR, not reached.
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and PDGF-C in stroma (r  0.20, p  0.001), but no
correlation between VEGF-A and PDGF-C expression in
tumor cells (r  0.08, p  0.17) or tumor cell VEGF-A and
stromal PDGF-C (r  0.05, p  0.29).
DISCUSSION
We present a large-scale study using high-throughput
TMA analyses, to examine the prognostic impact of PDGF-A,
TABLE 2. Tumor Cell and Stromal Angiogenic Markers as
Predictors for Disease-Specific Survival in 335 NSCLC
Patients (Univariate Analysis; Log-Rank Test)
Marker
Expression
Patients
(n)
Patients
(%)
Median
Survival
(mo)
5-Year
Survival
(%) p
PDGF-AA
Tumor
Low 158 47 NR 62 0.144
High 169 51 83 55
Missing 8 2
Stroma
Low 207 62 71 52 0.009
High 125 37 NR 68
Missing 3 1
PDGF-AB/BB
Tumor
Low 282 84 NR 60 0.001
High 52 16 30 44
Missing 1 0
Stroma
Low 210 63 83 53 0.04
High 125 37 NR 70
PDGF-CC
Tumor
Low 41 12 NR 82 0.01
High 288 86 84 55
Missing 6 2
Stroma
Low 218 65 127 56 0.29
High 113 34 NR 62
Missing 4 1
PDGF-DD
Tumor
Low 308 91 NR 60 0.20
High 22 7 42 41
Missing 5 2
Stroma
Low 299 89 84 55 0.019
High 32 10 NR 86
Missing 4 1
PDGFR-
Tumor
Low 129 39 NR 67 0.026
High 198 59 71 53
Missing 8 2
Stroma
Low 192 57 71 53 0.032
High 136 41 NR 65
Missing 7 2
PDGFR-
Tumor
Low 288 86 NR 59 0.84
High 42 12 127 51
Missing 5 2
Stroma
Low 262 78 127 57 0.16
High 69 21 NR 63
Missing 4 1
NSCLC, non-small cell lung cancer; PDGF, platelet-derived growth factor.
FIGURE 2. Disease-specific survival curves according to
stromal PDGF-A expression, tumor cell PDGF-B expression,
and tumor cell PDGFR- expression. PDGF, platelet-derived
growth factor.
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-B, -C, and -D and PDGFR- and - in both tumor cell and
stroma in an unselected population of surgically resected
NSCLC patients. High tumor cell PDGF-B and PDGFR-
expression were independent negative prognostic indicators
for DSS, whereas high stromal PDGF-A expression corre-
lated with a good prognosis.
To our knowledge, this is the first prognostic evaluation
of PDGFR- expression in NSCLC patients. Previous studies
in tumors as gastrointestinal stromal tumor,19 glioma,20 and
rhabdomyosarcoma21 have shown PDGFR- overexpression
to correspond with a poor prognosis. As shown in Figure 3,
PDGF ligands and receptors may be tumorigenic through
both autocrine mechanisms, which drive cancer cell prolifer-
ation and by activating stromal cells in a paracrine fash-
ion.10–12 In a model of human lung carcinoma, Tejada et al.22
demonstrated tumor-driven paracrine PDGFR- signaling to
be a key determinant of stromal recruitment. We observed
PDGFR- expression in viable neoplastic cells to be an
independent prognostic factor. Consistent with previous stud-
ies in gliomas and sarcomas,23,24 our results may indicate a
similar PDGFR- autocrine signaling in NSCLC tumors,
though our findings may also be explained by a paracrine
stimulation of PDGFR- in the tumor cells.
Both PDGF-A and -C are believed to promote angio-
genesis by stimulating VEGF-A production in the stromal
cells (Figure 3). This is in addition to the contribution of
VEGF-A by tumor cells. The role of PDGF-A has also been
studied by Shikada et al.,16 using cell lines and surgical
specimen of human NSCLCs. The authors demonstrated
PDGF-A as an autocrine, and probably also paracrine regu-
lator, making an essential contribution to the VEGF expres-
sion in NSCLC. Our data show that tumor cell PDGF-A
correlate with tumor cell VEGF-A and stromal PDGF-A with
stromal VEGF-A. This may be explained by PDGF-A as a
possible autocrine stimulator of VEGF-A in both tumor cells
and in stromal cells.
Consistent with a study by Kawai et al.15 in 92 NSCLC
patients, we identified tumor cell PDGF-B expression to be
an independent negative prognostic factor. The underlying
mechanism behind this association is still not resolved. Nev-
ertheless, studies on sophisticated mouse genetics have dem-
onstrated that proper PDGF receptor-dependent pericyte re-
cruitment relies on endothelial production of PDGF-B.25
Whether PDGF-B has a direct effect on endothelial cells
remain unclear.11 On the Basis of our results, although lack-
ing data on PDGFR-  expression in pericytes, one might
speculate whether tumor cell PDGF-B also contributes
through PDGF-B/PDGFR- activation to stimulate pericytes
during blood-vessel maturation. Another explanation to
PDGF-B’s negative prognostic impact is its possible contri-
bution to increased interstitial fluid pressure (IFP). Although
the precise mechanism behind increased IFP remains ob-
scure, evidence from preclinical studies indicate that
PDGF-B induces active participation of connective tissue
cells in controlling the IFP by altering the tension of the
structures in the extracellular matrix (e.g., by stimulation of
fibroblasts).26 In NSCLC xenografts exposed to imatinib,
Vlahovic et al.27 demonstrated a significant decrease in en-
TABLE 4. Crosstabs Showing the Correlation Between
Tumor Cell VEGF-A and Tumor Cell PDGF-A
Tumor Cell VEGF-A
Total
Low
Expression
High
Expression
Tumor cell PDGF-A
Low expression 113 44 157
High expression 73 96 169
Total 186 140 326
Spearman correlation, r  0.29,   0.29, p  0.001. VEGF, vascular endothelial
growth factor; PDGF, platelet-derived growth factor.
TABLE 5. Crosstabs Showing the Correlation Between
Stromal VEGF-A and Stromal PDGF-A
Stromal VEGF-A
Total
Low
Expression
High
Expression
Stromal PDGF-A
Low expression 197 10 207
High expression 93 32 125
Total 290 42 332
Spearman correlation, r  0.30,   0.24, p  0.001. VEGF, vascular endothelial
growth factor; PDGF, platelet-derived growth factor.
TABLE 3. Results of Cox Regression Analysis Summarizing
Significant Independent Prognostic Factors
Factor Hazard Ratio 95% CI P
Tumor status
1 1.00 0.002a
2 2.04 1.23–3.38 0.005
3 3.24 1.61–6.55 0.001
Nodal status
0 1.00 0.001a
1 2.05 1.34–3.14 0.001
2 2.71 1.53–4.81 0.001
Performance status
ECOG 0 1.00 0.013a
ECOG 1 1.81 1.22–2.70 0.003
ECOG 2 1.34 0.56–3.20 0.52
Vascular infiltration
No 1.00
Yes 2.07 1.27–3.36 0.003
PDGF-AB/BB Tumor
Low 1.00
High 2.12 1.35–3.31 0.001
PDGFR- Tumor
Low 1.00
High 1.52 1.01–2.30 0.047
PDGF-AA Stroma
Low 2.00 1.33–3.01 0.001
High 1.00
a Overall significance as a prognostic factor.
CI, Confidence interval; ECOG, Eastern Cooperative Oncology Group; PDGF,
platelet-derived growth factor.
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dothelial cell density and a trend towards a decreased fraction
of pericyte coverage. The authors concluded that this possibly
resulted from imatinib inhibition of PDGF-B/PDGFR-
through modified vasculature and decreased IFP.
The prognostic clinical significance of PDGF-C and -D
expression in NSCLC patients is herewith presented for the
first time. We identified tumor cell PDGF-C expression as a
negative prognostic factor in the univariate analysis. Tejada
et al.22 showed that PDGF-C expression is significantly up-
regulated in human lung tumors indicating tumor progression
through PDGFR- signaling. Our collective data17 also re-
vealed high stromal PDGF-C expression to correlate with
high stromal VEGF-A expression, indicating a possible
PDGF-C induced stromal VEGF-A formation.
Newly formed vessels, whether they are tumor-associ-
ated or not are particularly vulnerable to VEGF-A blockade.
On the other hand, mature endothelial cells, covered by extra-
cellular matrix and pericytes, may be resistant to VEGF-A
blockade or other antiangiogenic agents.12 This was early ques-
tioned in a pioneering study by Bergers et al.,28 demonstrating
that enhanced antiangiogenic effects could be achieved by
combining VEGF- and PDGF-antagonists, thereby obtaining
simultaneous antiendothelial and antipericyte effects. This
approach has been further developed by inclusion of drugs
directed predominantly against the epithelial compartment of
tumors.29 In NSCLC patients, Bauman et al.6 combined
bevacizumab and imatinib in patients without progression
from platinum doublet chemotherapy plus bevazicumab. The
aim was to test if targeting PDGFR and VEGF simulta-
neously is a more effective antiangiogenic strategy than
anti-VEGF alone. Multikinase inhibitors also target angio-
genesis through this dual approach. Sorafenib is inhibiting
both VEGFR-2, -3, and PDGFR-, whereas sunitinib targets
both PDGFRs and VEGFRs.7 Evaluations of these agents in
clinical phase II NSCLC studies show promising efficacy.
This corroborate our previous17 and present findings of a
significantly negative role of tumor cell VEGF-A, VEGFRs,
PDGFR-, and PDGF-B.
In contrast to the study by Shikada et al.,16 we did not
observe tumor cell PDGF-A expression as a significantly
negative prognostic factor for NSCLC patients. On the other
hand, we present novel data showing stromal PDGF-A ex-
pression as an independent positive prognostic factor in
NSCLC patients. The underlying mechanism to this some-
what surprising finding is debatable. This result also contra-
dicts a close interplay between tumor cell and tumor-related
FIGURE 3. PDGFs/PDGFRs role in the complex interplay between endothelial, tumor and stromal cells in angiogenesis. Yel-
low boxes: Summarizing some of previous findings.10–12 Red boxes: Our main results. PDGF, platelet-derived growth factor;
VEGF, vascular endothelial growth factor; TC, tumor cell; S, stromal; IFP, interstitial fluid.
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stroma as its receptor, the PDGFR-, is highly expressed on
the neighboring tumor cells and it is classified as a negative
prognostic indicator for DSS. Though the presented stromal
expression for each specific marker is the total expression of
different stromal cells, including lymphocytes, macrophages,
granulocytes, and fibroblast-like cells. Consequently, a pos-
sible explanation may be that the stromal PDGF-A expression
is linked to one or more stromal cell types. We know that the
immune system plays paradoxical roles in the defense against
malignancy. In general, activation of the adaptive immune
system may suppress malignant cells, whereas activation of
various types of innate immune cells may promote tumor
growth.30 Though based on only morphologic criteria without
any double IHC, we estimated more than 50% of our stromal
lymphocytes to express PDGF-A, hence high stromal
PDGF-A may to some extent reflect activation of the adaptive
immune system.
In the complex interplay between endothelial, stromal
and tumor cells, PDGF ligands and receptors are regarded as
major players in tumor development. Beyond confirming the
negative prognostic impact by tumor cell PDGF-B expres-
sion, we have demonstrated for the first time that tumor cell
PDGFR- expression is an independent negative prognostic
factor in NSCLC patients. Although further investigation is
needed to explain the underlying mechanisms, we have doc-
umented stromal PDGF-A expression as a positive indepen-
dent prognostic factor in NSCLC. As the cellular crosstalk
between endothelial, stromal and tumor cells combined is
important, targeting different cellular entities by VEGF and
PDGF related agents in combination with chemotherapy
seems to be an appealing approach.
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